Ribo’s siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia

On October 28, 2024, Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) received authorization from the Swedish Medicinal Product Agency (MPA), to initiate a Phase II clinical trial in Sweden with the lipid-lowering siRNA drug RBD5044 that targets APOC3. The trial will evaluate efficacy and safety in patients with mixed dyslipidemia. A randomized, […]

Privacy Policy (Integritetspolicy)
Your privacy is important to us. Ribocure Pharmaceuticals AB respects your privacy regarding all data we may collect from you on our website, www.ribocure.com.
 
We collect data/information to make contact and establish and maintain a relationship. We collect this information in a fair and legal way with your awareness and consent, as stipulated by GDPR (General Data Protection Regulation). We also let you know why we collect it and how it will be used.
 
The data that is stored are the fields that each submission form contains. We save the data for as long as is necessary with regard to the purposes of the processing. We always base the collection of personal data on consent.
 
You have the right to request information about what personal data we have stored about you. To do this, contact the Data Protection Officer (DPO). You also have the right to request correction or deletion of your personal data at any time.
 
Your continued use of our website will be deemed as acceptance of our privacy and personal information practices. If you have any questions about how we handle user data and personal information, please contact us.
 
Contact information to the Data Protection Officer (DPO):
 
Data Protection Officer
Ribocure Pharmaceuticals AB
Vetenskapens gränd 11
431 53 Mölndal
Sweden
 
E-mail: dpo@ribocure.com